SINGULAIR is a prescription medicine approved to help control symptoms of asthma in adults and children 12 months and older and for relief of symptoms of indoor and outdoor allergies (outdoor allergies in adults and children as young as 2 years and indoor allergies in adults and children as young as 6 months).
SINGULAIR has not been studied as a treatment option for both conditions in the same person.
IMPORTANT SAFETY INFORMATION
- SINGULAIR is not a rescue medication. Always carry a prescribed rescue inhaler for emergencies or sudden symptoms. If your or your child's asthma symptoms get worse or there is a need to increase the use of fast-acting medicines, call the doctor at once.
- Side effects vary by age and may include headache, ear infection, sore throat, and upper respiratory infection. Behavior and mood-related changes have been reported, including agitation, aggression or anger, bad or vivid dreams, depression, anxiety, hallucinations (seeing things that are not there), irritability, restlessness, sleepwalking, suicidal thoughts and actions (including suicide), trembling, and trouble sleeping. Tell the doctor if you have, or your child has, these or any other side effects while taking SINGULAIR.
- Parents or guardians of a phenylketonuric child: Note that cherry chewable tablets contain phenylalanine, a component of aspartame.
- SINGULAIR should not be taken by people who are sensitive to any of its ingredients.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please read the Patient Information and discuss it with your doctor. The physician Prescribing Information also is available.
SINGULAIR is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
20852779(5)-02/10-SNG



